This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort
Leukemia Open Access 15 July 2023
-
Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia
Annals of Hematology Open Access 08 August 2022
-
Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18
Scientific Reports Open Access 27 October 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.
Reiter A, Gotlib J . Myeloid neoplasms with eosinophilia. Blood 2017; 129: 704–714.
Vizmanos JL, Hernandez R, Vidal MJ, Larrayoz MJ, Odero MD, Marin J et al. Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol J 2004; 5: 534–537.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.
Schwaab J, Umbach R, Metzgeroth G, Naumann N, Jawhar M, Sotlar K et al. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol 2015; 90: 774–777.
Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol 2016; 29: 854–864.
Pardanani A, Lasho T, Wassie E, Finke C, Zblewski D, Hanson CA et al. Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia 2016; 30: 1924–1926.
Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 2015; 94: 233–238.
Maccaferri M, Pierini V, Di Giacomo D, Zucchini P, Forghieri F, Bonacorsi G et al. The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1-PDGFRB rearrangement and overview of PDGFRB partner genes. Leuk Lymphoma 2017; 58: 489–493.
Hamaguchi H, Nagata K, Yamamoto K, Fujikawa I, Kobayashi M, Eguchi M . Establishment of a novel human myeloid leukaemia cell line (FKH-1) with t(6;9)(p23;q34) and the expression of dek-can chimaeric transcript. Br J Haematol 1998; 102: 1249–1256.
Palau A, Mallo M, Palomo L, Rodriguez-Hernandez I, Diesch J, Campos D et al. Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia. Genes Chromosomes Cancer 2017; 56: 243–252.
Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia 2013; 27: 2254–2256.
Erben P, Gosenca D, Muller MC, Reinhard J, Score J, Del Valle F et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010; 95: 738–744.
Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM et al. High frequency and poor outcome of philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol 2017; 35: 394–401.
Acknowledgements
This work was supported by grant 13002 to NCPC from Bloodwise and the Deutsche José Carreras Leukämie-Stiftung e.V. (grant no. DJCLS R 13/05).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
NCPC has received honoraria and research support from Novartis and honoraria from Pfizer. AR has received honoraria and research support from Novartis. The other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Jawhar, M., Naumann, N., Knut, M. et al. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia 31, 2271–2273 (2017). https://doi.org/10.1038/leu.2017.240
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.240
This article is cited by
-
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort
Leukemia (2023)
-
Updates on eosinophilic disorders
Virchows Archiv (2023)
-
Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia
Annals of Hematology (2022)
-
Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18
Scientific Reports (2021)
-
Myeloid/lymphoid neoplasms with FLT3 rearrangement
Modern Pathology (2021)